目的 探究六味能消膠囊聯(lián)合蘭索拉唑和莫沙必利治療反流性食管炎的臨床療效。方法 選取2014年4月-2015年4月在山丹縣人民醫(yī)院接受治療的反流性食管炎患者92例，隨機(jī)分為對(duì)照組和治療組，每組各46例。對(duì)照組患者早晨飯后口服蘭索拉唑腸溶片，1片/次，1次/d；同時(shí)飯前口服枸櫞酸莫沙必利片，1片/次，3次/d。治療組患者在對(duì)照組的基礎(chǔ)上飯后口服六味能消膠囊，1粒/次，3次/d。兩組患者均每4周復(fù)查1次，連續(xù)治療8周。治療后，比較兩組患者臨床療效、癥狀積分以及不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為71.74%和86.96%，兩組總有效率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療2、4、8周后，兩組患者癥狀積分均較治療前明顯下降，同組治療前后差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療8周后治療組患者的癥狀改善情況明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組不良反應(yīng)發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 六味能消膠囊聯(lián)合蘭索拉唑和莫沙必利治療反流性食管炎療效顯著，能夠顯著抑制胃酸分泌，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore clinical effect of Liuwei Nengxiao Capsules combined with lansoprazole and mosapride in treatment of reflux esophagitis. Methods Patients (92 cases) with reflux esophagitis in Shandan People's Hospital from April 2014 to April 2015 were randomly divided into the control and treatment groups, and each group had 46 cases. The patients in the control group were po administered with Lansoprazole Enteric-coated Tablets after meals in the morning, 1 tablet/time, once daily. And they were po administered with Mosapride Citrate Tablets after meals, 1 tablet/time, three times daily. The patients in the treatment group were po administered with Liuwei Nengxiao Capsules after meals on the basis of the control group, 1 grain/time, three times daily. Patients in two groups were treated for 8 weeks and reviewed once every 4 weeks. After treatment, the clinical efficacy, main symptom scores and adverse reaction in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment group were 71.74% and 86.96%, respectively, and there were differences between two groups (P<0.05). After treatment for 2, 4, and 8 weeks, symptom scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the improvement of clinical symptom in treatment group treated for 8 weeks was better than that in the control group, with significant difference between two groups (P<0.05). There was no significant difference in adverse reactions rate between two groups. Conclusion Liuwei Nengxiao Capsules combined with lansoprazole and mosapride has a significant clinical effect in treatment of reflux esophagitis, can obviously inhibited the secretion of gastric acid, which has a certain clinical application value.